Skip to main content
. 2023 Oct 18;623(7985):157–166. doi: 10.1038/s41586-023-06623-2

Extended Data Table 2.

Demographics of subjects in dose-escalation phase 1 trial of CAN-3110 (Arm A: Cohort 10)

graphic file with name 41586_2023_6623_Tab2_ESM.jpg

(related to Sub-heading, Safety of CAN-3110 in rHGG/rGBM patients)

*One subject in cohort 9 (subject 042) was re-treated as part of cohort 10 (subject 054). See explanation in Supplemental Text.